Cilta-cel (ciltacabtagene autoleucel)

About Genscript Biotech

Founded in 2002 and publicly listed on the Hong Kong Stock Exchange, Genscript Biotech has evolved from a pioneering gene synthesis service provider into a fully integrated global biotechnology platform. The company operates through three core segments: Life Science Services and Products, Biologics Contract Development and Manufacturing (CDMO), and its own innovative cell therapy pipeline. Its strategic focus includes leveraging its strong R&D foundation to advance proprietary cell therapies while expanding its global CDMO footprint to capture the booming biologics and cell/gene therapy market.

Therapeutic Areas

Other Relapsed/Refractory Multiple Myeloma Drugs